ImmuCell Corporation to Announce Unaudited Financial Results for Q4 and Year-End 2025 on March 4, 2026

ImmuCell Corporation will report unaudited financial results on March 4, 2026, followed by a conference call March 5.

Quiver AI Summary

ImmuCell Corporation has announced its plans to release unaudited financial results for the quarter and year ending December 31, 2025, on March 4, 2026, after the market closes. A conference call will be held the following morning, March 5, 2026, at 9:00 AM ET, for reviewing these results, with access available via provided phone numbers. The preliminary sales figures disclosed on January 8, 2026, are expected to remain unchanged. The company will file its Annual Report on Form 10-K by March 31, 2026. ImmuCell focuses on developing products to enhance cattle health and productivity, including its First Defense® product for newborn calves. Additional information can be found on their website.

Potential Positives

ImmuCell Corporation is set to report unaudited financial results for the quarter and year ended December 31, 2025, which indicates transparency and commitment to informing stakeholders.
The Company anticipates no change to the preliminary sales results previously disclosed, suggesting stability and confidence in its financial performance.
The scheduled conference call to review financial results offers an opportunity for direct engagement with investors, enhancing communication and trust.
ImmuCell's ongoing commitment to develop products that improve cattle health and productivity aligns with market needs and may strengthen its competitive position in the animal health industry.

Potential Negatives

The announcement of unaudited financial results may indicate uncertainty and lack of finality in the company's performance reporting.
The expectation of no change in preliminary sales results may suggest stagnation or lack of growth in sales for the company.
The delay in filing the Annual Report on Form 10-K until March 31, 2026, could raise concerns about regulatory compliance and transparency with investors.

FAQ

When will ImmuCell report its financial results?

ImmuCell will report its unaudited financial results on March 4, 2026, after market close.

What is the date and time of the conference call?

The conference call is scheduled for March 5, 2026, at 9:00 AM ET.

How can I access the conference call?

Access the call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international).

Will there be a replay of the conference call?

Yes, a replay will be available until March 12, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international).

What product does ImmuCell manufacture?

ImmuCell manufactures First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ICCC Insider Trading Activity

$ICCC insiders have traded $ICCC stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ICCC stock by insiders over the last 6 months:

BOEKHORST PAUL FRANCIS OLIVIER TE (President and CEO) has made 3 purchases buying 9,785 shares for an estimated $48,588 and 0 sales.
DAVID SCOTT TOMSCHE has made 2 purchases buying 3,266 shares for an estimated $15,554 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ICCC Revenue

$ICCC had revenues of $5.5M in Q3 2025. This is a decrease of -8.41% from the same period in the prior year.

You can track ICCC financials on Quiver Quantitative's ICCC stock page.

$ICCC Hedge Fund Activity

We have seen 8 institutional investors add shares of $ICCC stock to their portfolio, and 12 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DAUNTLESS INVESTMENT GROUP, LLC removed 47,488 shares (-54.5%) from their portfolio in Q4 2025, for an estimated $292,051
SHUFRO ROSE & CO LLC removed 26,028 shares (-42.6%) from their portfolio in Q4 2025, for an estimated $160,072
STEADTRUST LLC added 25,070 shares (+79.1%) to their portfolio in Q4 2025, for an estimated $154,180
MESIROW FINANCIAL INVESTMENT MANAGEMENT, INC. added 24,303 shares (+199.6%) to their portfolio in Q4 2025, for an estimated $149,463
MORGAN STANLEY added 19,600 shares (+18.6%) to their portfolio in Q4 2025, for an estimated $120,540
CITADEL ADVISORS LLC removed 19,482 shares (-47.6%) from their portfolio in Q3 2025, for an estimated $121,762
PROSPERITY PLANNING, INC. removed 16,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $100,000

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026.

The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 12, 2026 at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.

The Company anticipates no change to the preliminary sales results for the quarter and year ended December 31, 2025 that were disclosed on January 8, 2026. The Company expects to file its Annual Report on Form 10-K on or before Tuesday, March 31, 2026.

About ImmuCell:
ImmuCell Corporation's ( Nasdaq: ICCC ) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets First Defense ^® , providing Immediate Immunity ™ to newborn dairy and beef calves. Press releases and other information about the Company are available at: http://www.immucell.com .

Contacts:	Olivier te Boekhorst, President and CEO
	Timothy C. Fiori, Chief Financial Officer
	ImmuCell Corporation
	[email protected]

	Joe Diaz, Robert Blum and Joe Dorame
	Lytham Partners, LLC
	[email protected]